Share on LinkedInShare on LinkedIn

ARTICLE · 01 APRIL 2024

More Lessons From Mumbai – Reflections On A Hatch-Waxman And PIV Litigation Panel Discussion

Axinn LLP
Axinn LLP
Contributor
Axinn LLP

Axinn LLP

Incisive. Inclusive. Invested. We’re Axinn. Experienced, tenacious, and always trial-ready, we are...

View firm profile
Explore more from Axinn LLP

Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I moderated on Industry Insights...

United StatesIntellectual Property

Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I moderated on Industry Insights on Hatch-Waxman and Paragraph IV Litigation. The legal issues facing generic pharmaceutical companies are constantly in flux, and it was interesting to receive insights from the panelists – Gautam Bakshi, Head & Patent Counsel – Intellectual Property Management at Unichem Laboratories, Kaushal Joshi, Sr. Director IP & Legal at Kashiv BioSciences, and Madhav Trivedi, Associate Director IPR at Arcolab Private Ltd (a Strides group company).

Induced infringement issues and labeling carveouts following GSK v. Teva are always hot topics at pharmaceutical patent conferences. The panelists explained that, when facing method-of-use patents, their internal teams always start by evaluating whether it is possible to avoid such patents by carving out indications or language from their proposed product

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from